Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

BACKGROUND: Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-κB ligand, on bone mi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Smith, Matthew R., Egerdie, Blair, Toriz, Narciso Hernández, Feldman, Robert, Tammela, Teuvo L.J., Saad, Fred, Heracek, Jiri, Szwedowski, Maciej, Ke, Chunlei, Kupic, Amy, Leder, Benjamin Z., Goessl, Carsten
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3038121/
https://ncbi.nlm.nih.gov/pubmed/19671656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0809003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars